The FDA has granted priority review designation to Galt Pharmaceuticals' supplemental abbreviated new drug application for Orphengesic Forte, a combination nonopioid analgesic. The agency has set a PDUFA date of Aug. 14.
FDA prioritizes review of Galt's opioid-free analgesic
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.